These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39051006)

  • 21. Relationship between Cefquinome PK/PD Parameters and Emergence of Resistance of Staphylococcus aureus in Rabbit Tissue-Cage Infection Model.
    Xiong M; Wu X; Ye X; Zhang L; Zeng S; Huang Z; Wu Y; Sun J; Ding H
    Front Microbiol; 2016; 7():874. PubMed ID: 27375594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
    Dorey L; Pelligand L; Cheng Z; Lees P
    J Vet Pharmacol Ther; 2017 Oct; 40(5):505-516. PubMed ID: 28090673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
    Dorey L; Pelligand L; Lees P
    BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentration-resistance relationship and PK/PD evaluation of danofloxacin against emergence of resistant Pasteurella multocida in an in vitro dynamic model.
    Lu TY; Sun Z; Liang LY; Zhang J; Guo WL; Wang ZY; Sun J; Liao XP; Zhou YF
    J Appl Microbiol; 2024 Jul; 135(7):. PubMed ID: 38925653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulatory effects of tulathromycin on apoptosis, efferocytosis, and proinflammatory leukotriene B4 production in leukocytes from Actinobacillus pleuropneumoniae-or zymosan-challenged pigs.
    Duquette SC; Fischer CD; Williams AC; Sajedy S; Feener TD; Bhargava A; Reti KL; Muench GP; Morck DW; Allison J; Lucas MJ; Buret AG
    Am J Vet Res; 2015 Jun; 76(6):507-19. PubMed ID: 26000598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance.
    Xu L; Wang H; Yang X; Lu L
    BMC Vet Res; 2013 Jun; 9():126. PubMed ID: 23800340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of tulathromycin in edible tissues of healthy and experimentally infected pigs with Actinobacillus pleuropneumoniae.
    Bladek T; Posyniak A; Jablonski A; Gajda A
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2015; 32(11):1823-32. PubMed ID: 26247868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf.
    Toutain PL; Potter T; Pelligand L; Lacroix M; Illambas J; Lees P
    J Vet Pharmacol Ther; 2017 Jan; 40(1):16-27. PubMed ID: 27501187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic/pharmacodynamic evaluation of marbofloxacin in the treatment of Haemophilus parasuis and Actinobacillus pleuropneumoniae infections in nursery and fattener pigs using Monte Carlo simulations.
    Vilalta C; Giboin H; Schneider M; El Garch F; Fraile L
    J Vet Pharmacol Ther; 2014 Dec; 37(6):542-9. PubMed ID: 24903473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of
    Somogyi Z; Mag P; Simon R; Kerek Á; Makrai L; Biksi I; Jerzsele Á
    Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PK/PD Integration and Resistance of Tilmicosin against
    Huang Z; Hu Z; Zheng H; Xia X; Gu X; Shen X; Yang H; Ding H
    Pathogens; 2020 Jun; 9(6):. PubMed ID: 32575357
    [No Abstract]   [Full Text] [Related]  

  • 32. Analysis of the mutant selection window and killing of Mycoplasma hyopneumoniae for doxycycline, tylosin, danofloxacin, tiamulin, and valnemulin.
    Huang Z; Mao C; Wei Y; Gu X; Cai Q; Shen X; Ding H
    PLoS One; 2020; 15(6):e0220350. PubMed ID: 32544163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics/pharmacodynamics integration of tilmicosin against Mycoplasma synoviae in vitro and in vivo.
    Yan X; Liu J; Li W; Song S; Yao Z; Jia Y; Yuan S; Yang H; Zhang N
    J Vet Pharmacol Ther; 2024 Nov; 47(6):503-511. PubMed ID: 39135274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.
    Kesteman AS; Ferran AA; Perrin-Guyomard A; Laurentie M; Sanders P; Toutain PL; Bousquet-Mélou A
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4740-8. PubMed ID: 19738020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
    Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
    BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.
    Mei Q; Ye Y; Zhu YL; Cheng J; Chang X; Liu YY; Li HR; Li JB
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):737-44. PubMed ID: 25424036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant prevention concentration, pharmacokinetic-pharmacodynamic integration, and modeling of enrofloxacin data established in diseased buffalo calves.
    Ramalingam B; Sidhu PK; Kaur G; Venkatachalam D; Rampal S
    J Vet Pharmacol Ther; 2015 Dec; 38(6):529-36. PubMed ID: 25776301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
    Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica.
    Blondeau JM; Borsos S; Blondeau LD; Blondeau BJ; Hesje CE
    Vet Microbiol; 2012 Nov; 160(1-2):85-90. PubMed ID: 22677482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine
    Luo W; Wang D; Qin H; Chen D; Pan Y; Qu W; Huang L; Xie S
    J Vet Sci; 2021 Nov; 22(6):e41. PubMed ID: 34854264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.